严重急性呼吸综合征冠状病毒2型(severe acute respiratory syndrome coronavirus 2，SARS-CoV-2)引起的2019冠状病毒病(coronavirus disease 2019，COVID-19)呈现出两个高比例态势，一是病毒感染者合并高血压比例较高；二是合并高血压的病毒感染者发展为重症和危重病例的比例高。这提示病毒感染与高血压之间存在密切联系，因此对高血压患者这一特殊群体的合理用药提出了需求。本文通过分析血管紧张素转换酶 2(angiotensin converting enzyme 2，ACE2)，即SARS-CoV-2的功能性受体与ACE之间的平衡关系，探讨高血压与病毒易感性之间的联系，以及高血压人群罹患COVID-19可能的发病规律。由于高血压群体中，血管紧张素转换酶抑制剂(angiotensin converting enzyme inhibitors, ACEI)的应用占有重要地位，本文从药理学和病原学角度进行分析，对该人群病毒感染前后的高血压用药给出指导建议，以供临床参考。

Two subgroups of coronavirus disease 2019(COVID-19) patients deserved special medical attention, one being hypertension patients, the other being hypertension patients treated with angiotensin converting enzyme inhibitors (ACEI). Relatively high susceptibility of hypertension patients to the disease and severe prognosis for the ones using ACEI indicate that there is a close relationship between virus infection and hypertension, which puts forward the demand for rational medication for the special group of patients with hypertension. In this paper, we analyzed the balance between angiotensin converting enzyme 2 (ACE2), the functional receptor of SARS-CoV-2, and ACE, and then discussed the relationship between hypertension and virus susceptibility, as well as the possible pathogenesis of COVID-19 in hypertension. Because the angiotensin converting enzyme inhibitors (ACEI) play an important role in the population of hypertension, we give guidance and suggestions on the medication of hypertension before and after virus infection in this population for clinical reference in this paper by the analysis of pharmacology and etiology.